Immunocore to Present at 32nd Annual JP Morgan Healthcare Conference
News Jan 16, 2014
Immunocore Limited has announced that it will present at the 32nd annual JP Morgan Healthcare Conference on Thursday 16 January 2014 at 11:30 am (Pacific Time) at the Westin St Francis Hotel, San Francisco.
James Noble, Chief Executive Officer, will present a corporate update and data from Immunocore’s most advanced ImmTAC programme, IMCgp100, for the treatment of late stage melanoma.
Phase I testing was completed in late 2013, with promising early signs of efficacy indicated, and the company has initiated a Phase IIa trial in the UK and USA designed to optimize the dosing regimen and maximize the efficacy of IMCgp100.
Last week Immunocore has announced its third partnership deal in six months - an oncology research collaboration and licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca.
Both companies will research and develop novel cancer therapies using Immunocore’s ImmTAC technology.
Immunocore’s novel bi-specific biologics platform exploits the power of the body’s own immune system to find and kill diseased cells. ImmTACs direct a patient’s T cells to specifically destroy only the cancerous cells, avoiding damage to healthy cells.
Immunocore also has major discovery collaborations ongoing with leading pharmaceutical companies Genentech and GlaxoSmithKline.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE